耐多药和利福平耐药结核病预防性治疗的影响超出试验估计
研究建立基于个体的家庭结构结核传播模型,模拟印度家庭接触者调查,比较耐多药/利福平耐药结核病预防性治疗(MDR/RR-TPT)方案与无TPT或家庭干预。结果显示,2年观察期内MDR/RR-TPT可预防72%的MDR/RR-TB发病,需治疗人数(NNT)为73,延长观察、考虑传播效应及主动筛查后NNT降至54、27和12。
要点
- 模型模拟显示MDR/RR-TPT在2年内可预防72%的MDR/RR-TB发病。
- 预防1例MDR/RR-TB的NNT为73,延长观察至13-18年降至54。
- 考虑下游传播和主动筛查后NNT分别降至27和12。
核心结论
- 若即将完成的试验证实有效,MDR/RR-TB接触者TPT的长期人群影响可能远大于试验结果所示。
研究设计与样本
- 基于个体的家庭结构结核与MDR/RR-TB传播模型,校准至印度示例地区,模拟家庭接触者调查。
- 比较MDR/RR-TPT方案(假设6个月疗程、70%效力)联合主动病例发现与无TPT的接触者调查或无家庭干预。
主要发现
- 模拟典型试验2年观察,MDR/RR-TPT预防72%(四分位距45%-100%)的MDR/RR-TB发病。
- 预防1例MDR/RR-TB的NNT中位数为73(对比安慰剂)。
- 观察13-18年NNT降至54,考虑下游传播效应降至27,包含主动筛查效果降至12。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Several clinical trials of tuberculosis preventive treatment (TPT) for household contacts of patients with multidrug- or rifampin-resistant tuberculosis (MDR/RR-TB) are nearing completion. The potential benefits of delivering TPT to MDR/RR-TB contacts extend beyond the outcomes that clinical trials can measure. METHODS: We developed an agent-based, household-structured TB and MDR/RR-TB transmission model, calibrated to an illustrative setting in India. We simulated contact investigation in households of patients with MDR/RR-TB, comparing an MDR/RR-TPT regimen (assuming 6-month duration, 70% efficacy) and associated active case finding against alternatives of contact investigation without TPT or no household intervention. We simulated the TB and MDR/RR-TB incidence averted relative to placebo over 2 years, as measurable by a typical trial, as well as the incidence averted over a longer time horizon, in the broader population, and relative to no contact investigation. RESULTS: Observing TPT and placebo recipients for 2 years as in a typical trial, MDR/RR-TPT was measured to prevent 72% (interquartile range, 45%-100%) of incident MDR/RR-TB among recipients; the median number needed to treat (NNT) to prevent 1 MDR/RR-TB case was 73, compared to placebo. This NNT decreased to 54 with 13-18 years of observation, to 27 when downstream transmission effects were also considered, and to 12 when the effects of active TB screening were included by comparing to a no-household-contact-intervention scenario. CONCLUSIONS: If forthcoming trial results demonstrate efficacy, the long-term population impact of TPT for MDR/RR-TB-including the large effect of increased active TB detection among MDR/RR-TB contacts-could be much greater than suggested by trial outcomes alone.
引用
- Kasaie P, Pennington J, Gupta A, et al. The Impact of Preventive Treatment for Multidrug- and Rifampin-Resistant Tuberculosis Exceeds Trial-Based Estimates. Clin Infect Dis. 2024. PMID: 37724763. doi:10.1093/cid/ciad557
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。